✦ LIBER ✦

An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes

✍ Scribed by Goldberg, Stuart L.; Fenaux, Pierre; Craig, Michael D.; Gyan, Emmanuel; Lister, John; Kassis, Jeannine; Pigneux, Arnaud; Schiller, Gary J.; Jung, JungAh; Jane Leonard, E.; Fingert, Howard; Westervelt, Peter

Book ID: 125825949
Publisher: Elsevier
Year: 2014
Tongue: English
Weight: 329 KB
Volume: 3
Category: Article
ISSN: 2213-0489
DOI: 10.1016/j.lrr.2014.06.003

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Investigational Aurora A kinase inhibito

Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: Phase 1 dose-escalation study

✍ Falchook, Gerald; Kurzrock, Razelle; Gouw, Launce; Hong, David; McGregor, Kimber 📂 Article 📅 2014 🏛 Springer US 🌐 English ⚖ 856 KB

Phase I study of MLN8237—investigational

Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia

✍ Kelly, Kevin R.; Shea, Thomas C.; Goy, André; Berdeja, Jesus G.; Reeder, Craig B 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 542 KB

Phase II study of MLN8237 (alisertib), a

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

✍ Ursula A. Matulonis; Sudarshan Sharma; Sharad Ghamande; Michael S. Gordon; Salva 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 408 KB

Phase 1/2 study of weekly paclitaxel wit

Phase 1/2 study of weekly paclitaxel with or without alisertib, an investigational aurora a kinase inhibitor: Phase 1 results in patients with recurrent epithelial ovarian, fallopian tube, primary peritoneal, or breast cancer

✍ G. Falchook; B. Goff; R. Kurzrock; H. Gray; L. Martin; R. Coleman; H. Xiao; X. Z 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 132 KB

A Phase I study to assess the safety, ph

A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia

✍ Kosuke Tsuboi; Toshiya Yokozawa; Toru Sakura; Takashi Watanabe; Shin Fujisawa; T 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 239 KB

Clofarabine in combination with a standa

Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial)

✍ Willemze, R.; Suciu, S.; Muus, P.; Halkes, C. J. M.; Meloni, G.; Meert, L.; Karr 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 197 KB